Compare CRDL & LPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRDL | LPA |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.3M | 89.2M |
| IPO Year | N/A | N/A |
| Metric | CRDL | LPA |
|---|---|---|
| Price | $0.99 | $2.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 642.4K | 30.6K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.21 |
| Revenue | N/A | ★ $47,536,343.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $12.91 |
| Revenue Growth | N/A | ★ 7.28 |
| 52 Week Low | $0.77 | $2.55 |
| 52 Week High | $1.59 | $11.47 |
| Indicator | CRDL | LPA |
|---|---|---|
| Relative Strength Index (RSI) | 44.88 | 44.58 |
| Support Level | $0.88 | $2.65 |
| Resistance Level | $1.03 | $3.15 |
| Average True Range (ATR) | 0.05 | 0.17 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 7.29 | 52.68 |
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns, and manages a diversified portfolio of warehouse logistics assets in Central America and South America. It focuses on modern Class A logistics real estate in high-growth and high-barrier-to-entry markets that are undersupplied and have low penetration rates. The company has three operating segments, based on geographic regions, consisting of Colombia, Peru, and Costa Rica. The company generates the majority of its revenue from the Costa Rica geographical segment.